Búsqueda del medicamento por su nombre

Plazomicin y Disfuncion renal

Resultado de la verificación de la interacción del medicamento Plazomicin y la enfermedad de Disfuncion renal en la seguridad cuando se comparte.

Resultado de la verificación:

Plazomicin <> Disfuncion renal

Relevancia: 23.07.2019 Examinador: P.M. Shkutko, M.D., in

Al verificar la interacción según fuentes acreditadas Drugs.com, Rxlist.com, Webmd.com, Medscape.com contraindicaciones o efectos secundarios se han encontrado que pueden causar daño o aumentar el efecto negativo cuando el medicamento se usa con esta enfermedad concomitante.

Consumidor:

Los aminoglucósidos son potencialmente oto - y nefrotóxico. Octavo nervio craneal daño puede manifestarse como vestibular y/o auditivo efectos secundarios, como mareos, nistagmo, vértigo, ataxia, tinnitus, y diferentes grados de deterioro de la audición. La nefrotoxicidad se manifiesta en general por necrosis tubular; el aumento de BUN, nitrógeno no proteínico, y la concentración sérica de creatinina disminuye en la orina de la gravedad específica y el aclaramiento de creatinina, proteinuria; y las células o cilindros en la orina. Rara vez, renal, electrolitos perder puede ocurrir, resultando en hipocalcemia, hipomagnesemia, y la hipopotasemia que puede estar asociada con parestesia, tetania, la confusión y el positivo de Chvostek y Trousseau signos. Aunque inducida por aminoglucósidos nefrotoxicidad es generalmente reversible después de la discontinuación de la droga, la muerte por uremia ha ocurrido muy pocas veces. La terapia con aminoglucósidos debe ser administrado con cautela en la reducción de las dosis en pacientes con insuficiencia renal, ya que pueden estar en mayor riesgo de oto y nefrotoxicidad debido a la acumulación del fármaco. Para minimizar el riesgo de toxicidad, los pacientes deben estar adecuadamente hidratados, la habitual dosis de aminoglucósidos no deben ser excedidos, utilice con otros neuro - y nefrotóxicos debe ser evitado, y máximos y mínimos en el suero de los aminoglucósidos concentraciones deben ser periódicamente determinado y se debe ajustar la dosis para mantener los niveles deseados. Renal y octavo nervio craneal función debe ser monitoreado de cerca, y la reducción de la dosis o la retirada de la terapia si la toxicidad se desarrolla.

Fuentes

Kumin GD "Clinical nephrotoxicity of tobramycin and gentamicin." JAMA 244 (1980): 1808-10
Jaffe, Meyers BR, Hirschman SZ "Pharmacokinetics of tobramycin in patients with stable renal impairment, patients undergoing peritoneal dialysis, and patients on chronic hemodialysis." Antimicrob Agents Chemother 5 (1974): 611-6
Contreras AM, Gamba G, Cortes J, et al "Serial trough and peak amikacin levels in plasma as predictors of nephrotoxicity." Antimicrob Agents Chemother 33 (1989): 973-6
American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association; (1994):
Sarubbi FA, Hull JH "Amikacin serum concentrations: prediction of levels and dosage guidelines." Ann Intern Med 89 (1978): 612-8
"Product Information. Garamycin (gentamicin)." Schering-Plough Corporation, Kenilworth, NJ.
"Product Information. Streptomycin (streptomycin)." Pfizer US Pharmaceuticals, New York, NY.
Matzke GR, Millikin, Kovarik JM "Variability in pharmacokinetic values for gentamicin, tobramycin, and netilmicin in patients with renal insufficiency." Clin Pharm 8 (1989): 800-6
Matz GJ, Naunton RF "Ototoxic drugs and poor renal function." JAMA 206 (1968): 2119
French MA, Cerra FB, Plaut ME, Schentag JJ "Amikacin and gentamicin accumulation pharmacokinetics and nephrotoxicity in critically ill patients." Antimicrob Agents Chemother 19 (1981): 147-52
Pedersen SS, Jensen J, Osterhammel D, Osterhammel P "Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis." Antimicrob Agents Chemother 31 (1987): 594-9
Fanning WL, Gump D, Jick H "Gentamicin and cephalothin-associated rises in blood urea nitrogen." Antimicrob Agents Chemother 10 (1976): 80-2
Craig WA, Gudmundsson S, Reich RM "Netilmicin sulfate: a comparative evaluation of antimicrobial activity, pharmacokinetics, adverse reactions and clinical efficacy." Pharmacotherapy 3 (1983): 305-15
Humbert G, Leroy A, Fillastre JP, Oksenhendler G "Pharmacokinetics of netilmicin in the presence of normal or impaired renal function." Antimicrob Agents Chemother 14 (1978): 40-4
Kunin CM, Finland M "Persistence of antibiotics in blood of patients with acute renal failure. III. Penicillin, streptomycin, erythromycin and kanamycin." J Clin Invest 38 (1959): 1509-19
Smith CR, Lipsky JJ, Laskin OL, et al "Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin." N Engl J Med 302 (1980): 1106-9
Pijck J, Hallynck T, Soep H, Baert L, Daniels R, Boelaert J "Pharmacokinetics of amikacin in patients with renal insufficiency: relation of half-life and creatinine clearance." J Infect Dis 134 (1976): s331-41
Letona JM, Barbolla L, Frieyro E, et al "Immune haemolytic anaemia and renal failure induced by streptomycin." Br J Haematol 35 (1977): 561-71
"Product Information. Mycifradin (neomycin)." Emerson Laboratories, Texarkana, TX.
"Product Information. Nebcin (tobramycin)." Lilly, Eli and Company, Indianapolis, IN.
Herrero A, Alarco FR, Diez JM, Mahiques E, Domingo JV "Pharmacokinetics of netilmicin in renal insufficiency and hemodialysis." Int J Clin Pharmacol Ther Toxicol 26 (1988): 84-7
Madhavan T, Yaremchuk K, Levin N, et al "Effect of renal failure and dialysis on the serum concentration of the aminoglycoside amikacin." Antimicrob Agents Chemother 10 (1976): 464-5
Wilkinson R, Lucas GL, Heath DA, et al "Hypomagnesaemic tetany associated with prolonged treatment with aminoglycosides." Br Med J 292 (1986): 818-9
Luft FC, Brannon DR, Stropes LL, Costello RJ, Sloan RS, Maxwell DR "Pharmacokinetics of netilmicin in patients with renal impairment and in patients on dialysis." Antimicrob Agents Chemother 14 (1978): 403-7
"Product Information. Amikin (amikacin)." Bristol-Myers Squibb, Princeton, NJ.
Keys TF, Kurtz SB, Jones JD, Muller SM "Renal toxicity during therapy with gentamicin or tobramycin." Mayo Clin Proc 56 (1981): 556-9
Yoshikawa TT, Nagami PH "Adverse drug reactions in TB therapy: risks and recommendations." Geriatrics 37 (1982): 61-3, 67-8
Federspil P, Schatzle W, Tiesler E "Pharmacokinetics and ototoxicity of gentamicin, tobramycin and amikacin." J Infect Dis 134 (1976): s200-5
Siegenthaler WE, Bonetti A, Luthy R "Aminoglycoside antibiotics in infectious diseases: an overview." Am J Med 80 (1986): 2-14
McQueen EG "Antibiotic allergy and acute renal failure." N Z Med J 64 (1965): 561-3
Bergeron MG, Lessard C, Ronald A, Stiver G, Van Roogen CE, Chadwick P "Three to eight weeks of therapy with netilmicin: toxicity in normal and diabetic patients." J Antimicrob Chemother 12 (1983): 245-8
Emanuelli G, Anfossi G, Calcamuggi G, Marcarino C, Lanzio M "Urinary enzyme release following aminoglycoside administration in single low dose." Enzyme 39 (1988): 119-22
Williams PJ, Hull JH, Sarubbi FA, Rogers JF, WArgin WA "Factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin." J Clin Pharmacol 26 (1986): 79-86
Solberg CO, Madsen ST, Digranes A, et al "High dose netilmicin therapy: efficacy, tolerance and tissue penetration." J Antimicrob Chemother 6 (1980): 133-41
Ristuccia AM, Cunha BA "The aminoglycosides." Med Clin North Am 66 (1982): 303-12
Lerner SA, Schmitt BA, Seligsohn R, Matz G "Comparative study of ototoxicity and nephrotoxicity in patients randomly assigned to treatment with amikacin or gentamicin." Am J Med 80 Suppl 6 (1986): 98-104
Gyselnyck AM, Forrey A, Cutler R "Pharmacokinetics of gentamicin: distribution and plasma and renal clearance." J Infect Dis 124 (1971): s70
Bock BV, Edelstein PH, Meyer RD "Prospective comparative study of efficacy and toxicity of netilmicin and amikacin." Antimicrob Agents Chemother 17 (1980): 217-25
"Product Information. Netromycin (netilmicin)." Schering Laboratories, Kenilworth, NJ.
Trollfors B, Alestig K, Krantz I, Norrby R "Quantitative nephrotoxicity of gentamicin in nontoxic doses." J Infect Dis 141 (1980): 306-9
Bhattacharya BK, Gorringe H, Farr MJ "Netilmicin and nephrotoxicity." Lancet 2 (1983): 216-7
Pines A, Goldhammer E, Kaplinsky N, Frankl O "Hypopotassemia associated with tobramycin treatment." Infection 10 (1982): 101-
Pechere JC, Dugal R, Pechere MM "Pharmacokinetics of netilmicin in renal insufficiency and haemodialysis." Clin Pharmacokinet 3 (1978): 395-406
Cimino MA, Rotstein C, Slaughter RL, Emrich LJ "Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy." Am J Med 83 (1987): 1091-7
Gatell JM, SanMiguel JG, Araujo V, et al "Prospective randomized double-blind comparison of nephrotoxicity and auditory toxicity of tobramycin and netilmicin." Antimicrob Agents Chemother 26 (1984): 766-9
Schentag JJ, Lasezkay G, Cumbo TJ, et al "Accumulation pharmacokinetics of tobramycin." Antimicrob Agents Chemother 13 (1978): 649-56
Russo ME, Atkin-Thor E "Gentamicin and ticarcillin in subjects with end-stage renal disease." Clin Nephrol 15 (1981): 175-80
McHenry MC, Wagner JG, Hall PM, Vidt DG, Gavan TL "Pharmacokinetics of amikacin in patients with impaired renal function." J Infect Dis 134 Suppl (1976): s343-54
Plantier J, Forrey AW, O'Neill MA, Blair AD, Christopher TG, Cutler RE "Pharmacokinetics of amikacin in patients with normal or impaired renal function: radioenzymatic acetylation assay." J Infect Dis 134 Suppl (1976): s323-30
Dahlgren JG, Anderson ET, Hewitt WL "Gentamicin blood levels: a guide to nephrotoxicity." Antimicrob Agents Chemother 8 (1975): 58-62
Tablan OC, Reyes MP, Rintelmann WF, Lerner AM "Renal and auditory toxicity of high-dose, prolonged therapy with gentamicin and tobramycin in pseudomonas endocarditis." J Infect Dis 149 (1984): 257-63
Gilbert DN, Bennett WM "Use of antimicrobial agents in renal failure." Infect Dis Clin North Am 3 (1989): 517-31
Schentag JJ, Cerra FB, Plaut ME "Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients." Antimicrob Agents Chemother 21 (1982): 721-6
Bernstein JM, Gorse GJ, Linzmayer MI, et al "Relative efficacy and toxicity of netilmicin and tobramycin in oncology patients." Arch Intern Med 146 (1986): 2329-34
Watson AJ, Watson MM, Keogh JA "Metabolic abnormalities associated with tobramycin therapy." Isr J Med Sci 153 (1984): 96-9
Beauchamp D, Gourde P, Theriault G, Bergeron MG "Age-dependent gentamicin experimental nephrotoxicity." J Pharmacol Exp Ther 260 (1992): 444-9
Contrepois A, Brion N, Garaud JJ, et al "Renal disposition of gentamicin, dibekacin, tobramycin, netilmicin, and amikacin in humans." Antimicrob Agents Chemother 27 (1985): 520-4